A total of @ ET patients received IFN-@b therapy with JAK@V@F positive or negative mutation ; and @ PV patients with JAK@V@F ( + ) received IFN-@b or hydroxyurea ( HU ) therapy according to random number assignment ( ages @-@ years old ) .